These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1105560)

  • 1. A controlled trial of cyclophosphamide in the treatment of proliferative glomerulonephritis.
    Koelz AM; Morley AR; Uldall PR; Kerr DN
    Proc Eur Dial Transplant Assoc; 1975; 11():491-9. PubMed ID: 1105560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis.
    Woo KT; Edmondson RP; Yap HK; Wu AY; Chiang GS; Lee EJ; Pwee HS; Lim CH
    Clin Nephrol; 1987 Feb; 27(2):56-64. PubMed ID: 3549083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytostatic treatment of glomerular diseases. III. A double-blind cross-over study of the effect of cyclophosphamide report from a copenhagen study group of renal diseases.
    Balsløov JT; Brun C; Halberg P; Jensen KB; Jøorgensen F; Jrgensen HE; Larsen M; Larsen S; Lorenzen I; Thomsen AC
    Acta Med Scand; 1976; 200(1-2):31-36. PubMed ID: 785959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous "pulse" cyclophosphamide therapy of crescentic glomerulonephritis.
    Kunis CL; Kiss B; Williams G; D'Agati V; Appel GB
    Clin Nephrol; 1992 Jan; 37(1):1-7. PubMed ID: 1541058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of two cyclophosphamide treatment regimens in nephrotic patients with chronic glomerulonephritis].
    Krasnova TN; Shilov EM; Tareeva IE; Gordovskaia NB; Lavrova ON; Miroshnichenko NG; Troepol'skaia OV; Ivanova LV; Ivanov AA
    Ter Arkh; 1998; 70(6):14-7. PubMed ID: 9695216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cyclophosphamide pulse therapy in patients with primary glomerulonephritis].
    Rutkowski B; Wielgosz A; Manitius J; Bułło B; Kowalewska J; Tylicki L; Roszkiewicz A
    Przegl Lek; 2000; 57(11):624-7. PubMed ID: 11293209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of proliferative lupus glomerulonephritis: a prospective trial in The Netherlands.
    van den Wall Bake AW; Berden JH; Derksen RH; de Glas-Vos JW; Hagen EC
    Neth J Med; 1994 Dec; 45(6):280-4. PubMed ID: 7838244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal strategies for fertility preservation in patients receiving cyclophosphamide to treat glomerulonephritis: a nonrandomized trial and review of the literature.
    Cigni A; Faedda R; Atzeni MM; Pileri PV; Alagna S; Rovasio P; Satta AE; Loi MR; Sini A; Satta V; Masala A
    Am J Kidney Dis; 2008 Nov; 52(5):887-96. PubMed ID: 18971013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monitoring of the clinical and morphological course of glomerulonephritis].
    Pap I; Kemnitz P; Willgeroth Ch
    Z Urol Nephrol; 1978 Jun; 71(6):369-74. PubMed ID: 685514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
    Branten AJ; Wetzels JF
    Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive treatment of the glomerulonephritis of systemic lupus.
    Faedda R; Palomba D; Satta A; Pirisi M; Tanda F; Bartoli E
    Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic glomerulonephritis with a combination of indomethacin and cyclophosphamide.
    Vanrenterghem Y; Roels L; Verberckmoes R; Michielsen P
    Clin Nephrol; 1975 Dec; 4(6):218-22. PubMed ID: 1204260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of the effectiveness of Cyclophosphamide and Cytembena in controlled clinical trial in nephrotic syndrome and chronic glomerulonephritis].
    Sasinka M; Plenta I; Kaiserová E; Izakovic V; Pavlovic M; CYTEMBENA/*THER USE ; Slugen I; Lehký M; Stubna J
    Cesk Pediatr; 1976 Mar; 31(3):127-30. PubMed ID: 773556
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of idiopathic acute crescentic glomerulonephritis by immunodepression and plasma-exchanges. A prospective randomised study.
    Rifle G; Chalopin JM; Zech P; Deteix P; Ducret F; Vialtel P; Cordonnier D
    Proc Eur Dial Transplant Assoc; 1981; 18():493-502. PubMed ID: 7036171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crescentic glomerulonephritis in Wegener's granulomatosis: morphology, therapy, outcome.
    Grotz W; Wanner C; Keller E; Böhler J; Peter HH; Rohrbach R; Schollmeyer P
    Clin Nephrol; 1991 Jun; 35(6):243-51. PubMed ID: 1873937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between the VEGF levels and VEGF mRNA expression and clinical course in different glomerulonephritis.
    Paydas S; Balal M; Tanriverdi K; Sertdemir Y; Baslamisli F
    Ren Fail; 2007; 29(7):779-84. PubMed ID: 17994443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of immunosuppressive therapy of chronic glomerulonephritis in 400 patients].
    Müller V; Natusch R; Göbel U; Laske HR; Sperschneider H; Pap I; Sinn W; Koall W; Achenbach H; Tredt HJ
    Z Urol Nephrol; 1985 Jan; 78(1):39-55. PubMed ID: 3976309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of urinary excretion of fibrin degradation products during treatment of glomerulonephritis.
    Michielsen P; Roels L; Vanrenterghem Y; Boel A; van Damme B; Vermylen J
    Clin Nephrol; 1976 Mar; 5(3):105-13. PubMed ID: 1261101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.